- Home
- TLSI vs NERV Comparison
TLSI vs NERV Comparison
Compare TLSI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSI | NERV |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | 110 | 7 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.1M | 228.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TLSI | NERV |
|---|---|---|
| Price | $4.25 | $5.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | 190.8K | ★ 331.6K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $36.47 | N/A |
| Revenue Next Year | $39.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $1.15 |
| 52 Week High | $7.95 | $12.46 |
Technical Indicators
Market Signals| Indicator | TLSI | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 34.46 |
| Support Level | $3.79 | $3.69 |
| Resistance Level | $5.33 | $6.69 |
| Average True Range (ATR) | 0.24 | 0.65 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 81.82 | 0.85 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.